Revolutionizing Clinical Bioanalysis: Dash Bio Secures $6.5 Million in Seed Round Funding

Dash Bio is excited to announce that we have successfully raised $6.5 million in funding to further accelerate our mission of revolutionizing clinical bioanalysis and expediting drug development. Our innovative approach combines cutting-edge AI and robotics to deliver high-quality assays with turnaround times that are up to 10 times faster than the industry average for clinical trials and Good Laboratory Practice (GLP) studies. While many AI startups have made strides in drug discovery, we recognized a critical gap in the arduous development phase, which has traditionally relied on manual, labor-intensive processes. With this new infusion of capital, we are poised to enhance our tech-first product line, focusing on fully automating vital steps of clinical bioanalysis—testing samples from clinical trial subjects. Our modern platform smartly integrates quality, automation, and regulatory compliance, effectively streamlining processes while maintaining the highest standards. Led by our dynamic leadership team, including CEO Dave Johnson, former Chief Data and AI Officer at Moderna; COO Ander Tallett, who has rich experience leading Enterprise Systems at Moderna and Resilience; and CSO Ely Porter, co-founder and CTO of Rootpath, we are committed to creating a future where bioanalysis is intuitive and drug development is seamless. This funding will enable us to further innovate our offerings and enhance customer experiences and outcomes. We invite you to join us in this transformative journey. Together, we can change the landscape of drug development for good. To learn more, visit us at dash.bio.